๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2025-10-17

CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth (NCT05405413)

๐ŸŸข Recruiting Phase2 ๐Ÿ“‹ Clinical Research Protocol Sponsor: Dartmouth-Hitchcock Medical Center

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This is a single-arm Phase II study to measure the impact of Molecular Tumor Board treatment recommendations on treatment decision-making in clinical practice at the Dartmouth Cancer Center. Following tumor genetic profiling, subjects will be screened for eligibility. Eligible subjects' cases will be evaluated by the Dartmouth Cancer Center Molecular Tumor Board, and treatment recommendations will be entered into the medical record as per standard procedure. The primary endpoint is a survey response from the treating physician indicating how Molecular Tumor Board evaluation impacted treatment decisions. Secondary endpoints include: 1) Molecular Tumor Board treatment recommendation; 2) disease progression on line of therapy started after MTB recommendations were made. Surveys will be administered approximately 3 and 12 months after Molecular Tumor Board recommendations are made.

Who can join: Review the eligibility criteria below.

Location: Dartmouth-Hitchcock Medical Center โ€” Lebanon, New Hampshire

Age range: 18 Years

๐Ÿงช Interventions in This Study

  • Treatment recommendations made by Molecular Tumor Board. (OTHER)

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Dartmouth-Hitchcock Medical Center โ€” Lebanon, New Hampshire

๐Ÿ“ž Contact the Study Coordinator

Phone: (603) 650-7211

Email: laura.j.tafe@hitchcock.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Cancer clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—